ClinicalTrials.gg
CompletedNCT03354897UMODUpdated Sep 25, 2023

Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension

A Phase 4 interventional study of Torasemide 5Mg Tablet in Cardiovascular Diseases and Hypertension, sponsored by NHS Greater Glasgow and Clyde. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-25.

Primary conditionHypertensionRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypertension
Why
  1. The study's listed conditions name Hypertension, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NHS Greater Glasgow and Clyde · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Apr 2017, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
228
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 223 studies in Hypertension with a site in United Kingdom — 35 open to participants now, 43 under way, 7 of them phase 3. Hypertension · United Kingdom.

Enrollment
66th of 172
228 · median 125
Started
2017
with 12 others
Phase 4
20 of 223
1 open now
Registered
122nd of 223
by date

Among the 223 studies in Hypertension with a site in United Kingdom, this one is the 66th largest by enrollment of the 172 interventional ones that give a count, is one of 13 that started in 2017, is one of 20 in phase 4, and was the 122nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

35 of the 223 studies in Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 223 studies in Hypertension with a site in United Kingdom, or all of them as a file.
02

Study summary

The hypothesis is based on UMOD rs13333226 genotype, there are two strata of hypertensive patients. The High-UMOD group (AA genotype) has increased UMOD excretion, greater salt sensitivity, HTN, normal eGFR and greater BP response to loop diuretics like furosemide. The Low-UMOD group (G allele) has decreased UMOD excretion, salt resistance, increased eGFR, increased proximal tubular reabsorption of Na (possibly related to increased GFR), a poor BP response to loop diuretics, and possibly diminished function of NKCC2. The High-UMOD strata will have decreased delivery of Na+ to the distal tubule and collecting duct because NKCC2 function is normal and the study hypothesis is that the participants will be more responsive to loop diuretics. In contrast, the Low-UMOD group (G allele) will not show a similar response to loop diuretics. This may be related either to lower Na delivery to the TAL, because of increased proximal tubular reabsorption of Na+, or a suppressed function of NKCC2. The population distribution of the High-UMOD group (AA) is 67%. Our overall objective is to test the hypothesis that hypertensive subjects with uncontrolled HTN open possessing the AA genotype of rs13333226 will be better responders to loop diuretics compared to those possessing the G allele.

Read the detailed description

There are over 1 billion people with HTN worldwide, and the World Health Organisation suggests this will rise to 1.5 billion by 2020.(1) Up to 30% of hypertensive patients have resistant HTN (uncontrolled BP on > 3 drugs of which one must be a diuretic) and \~50% have uncontrolled HTN, with a 7-fold higher cardiovascular risk.

In clinical practice, criteria such as ancestry and serum renin levels provide only a rough indication of the underlying disease pathway and, while pharmacotherapy is the mainstay of HTN management, the selection of antihypertensive therapy is essentially by trial-and-error. Five drug classes are the main first-line agents for HTN, but response rates to any given drug are only \~50%. There are no new anti-hypertensive drugs in clinical trials and there is a need to either develop newer agents or target existing drugs to specific strata of hypertensive patients in whom they would be beneficial. The recent failure of the Renal Sympathetic Denervation trial, which used a novel device strategy for resistant HTN, highlights the limited options available in the management of uncontrolled or resistant HTN.

HTN as a phenotype demonstrates stratification in the population, based on the specific pathophysiological and molecular pathways that are operative and this is reflected in the current NICE guidelines. However, there has been little progress in stratification by leveraging genomic and molecular information, although there is evidence that this may be useful. Monogenic forms of HTN show that identification of the many causative mutations, primarily affecting the kidney and sodium balance, can inform therapy - for example, glucocorticoids in glucocorticoid remediable aldosteronism and amiloride in Liddle syndrome. Despite the successful adoption of the BHS/NICE treatment algorithm for the treatment of HTN, there remains substantial clinical uncertainty about the preferred clinical management of people with uncontrolled or treatment resistant HTN. Moreover, the choice of diuretic, suggested in HTN guidelines, is not based on clinical trials for third line antihypertensive agents. There is general consensus that resistant HTN is due to excessive sodium retention and thus "further diuretic therapy" may be an effective treatment. The choice that one type of diuretic will be superior to another has however not been studied and is usually prescribed in a trial and error manner with diuretics that primarily target the distal nephron (thiazide-like diuretic or spironolactone).

03

Conditions studied

  • Cardiovascular Diseases
  • Hypertension

Browse trials for

Keywords

  • stratified medicine, UMOD, torasemide
04

In context

Hypertension Reclassified

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

This study's enrollment of 228 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

NHS Greater Glasgow and Clyde is the lead sponsor of 220 studies on the registry; 39 are open to participants now.

Compared within Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hypertensive patients aged ≥18 years of age
  • Patients will all have hypertension that is not controlled to home target: SBP >135 mmHg and/or DBP >85 mmHg on therapy with one or more antihypertensive drugs for at least 3 months.
  • Able to attend one of the three study centres

Exclusion criteria

Exclusion Criteria:

  • Inability to give
  • Participation in a clinical study involving an drug or device within 3 months of screening
  • Secondary or accelerated hypertension (investigator opinion)
  • Diabetes mellitus (Type 1 or type 2)
  • \<60 mls/min, hyponatraemia, hypokalaemia
  • Pregnancy, breast feeding
  • Women of child bearing potential who are unwilling to use effective
  • is defined as women who have experienced menarche and who have not undergone successful surgical sterilisation or who are not (irregular menstrual periods, or amenorrhoea >12 months, with serum follicle stimulating hormone (FSH) >35mIU/ml; women taking hormone replacement therapy (HRT)
  • Women of childbearing potential will be eligible if they are willing to use acceptable contraception (combined oral contraceptives, progesterone only contraceptives, intrauterine device, barrier methods) or they are abstinence due to lifestyle choice or their partner is sterile (vasectomy).
  • Anticipated change of medical status during the trial (e.g. surgical intervention requiring >2 weeks convalescence)
  • Recent (\<6 months) cardiovascular event requiring hospitalisation (e.g. myocardial infarction or stroke)
  • Requirement for study drug or other loop diuretic for reason other than to treat hypertension
  • to treatment with torasemide: , hereditary problems of glucose intolerance, Lapp lactase deficiency of glucose-galactose malabsorption
  • Current therapy for cancer
  • Concurrent chronic illness, or other reasons likely to preclude 18-week participation in the study
  • Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety and/or efficacy of the study drug or severely limit that patients life-span or ability to complete the study (e.g. alcohol or drug abuse, disabling or terminal illness, severe liver impairment, mental disorders)
  • Treatment with any of the following medications -
  • Oral within 3 months of screening. Treatment with systemic corticosteroids is also prohibited during study participation
  • Chronic stable use, or unstable use of NSAIDs (other than low dose aspirin or occasional OTC analgesic doses) is prohibited. Chronic use is defined as >3 consecutive days of treatment per week. In addition intermittent use of NSAIDs is discouraged throughout the study. For those requiring analgesics during the study, paracetamol or opiate drugs are recommended.
  • Use of lithium
  • Participants on the following medications may be included provided they meet the following criteria
  • Use of thiazide or loop diuretics prior to the study if the diuretic can be stopped for 2 weeks (washout) before the study medication administered.
  • The use of short acting nitrates (e.g. sublingual nitroglycerin) is permitted. However, participants should avoid short acting oral nitrates within 4 hours of screening or an subsequent visit
  • The use of long acting nitrates (e.g. Isordil) is permitted but the dose must be stable for at least 2 weeks prior to screening and randomisation
  • The use of sympathomimetic decongestants is permitted, though not within 24 hours of any study visit/BP assessment
  • The use of theophylline is permitted but the dose must be stable for at least 4 weeks prior to screening and throughout the study
  • The use of phosphodiesterase type V inhibitors is permitted. However, study participants must refrain from taking these medications for at least 7 days prior to screening or any subsequent study visit
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
228 participants (actual)

Study arms

  • Other
    Treatment

    16 weeks treatment 5mg/day

    Drug: Torasemide 5Mg Tablet

Interventions

07

What researchers measure

Primary outcomes

  1. Change in ABPM

    Change in 24h ABPM systolic BP AUC at the end of the 16-week treatment phase compared to baseline

    Time frame: 16 weeks

Secondary outcomes

  1. change in 24h ABPM diastolic BP AUC

    change in 24h ABPM diastolic BP AUC between baseline and the end of treatment

    Time frame: 16 weeks

  2. change in day time ABPM systolic and diastolic BP AUC

    change in day time ABPM systolic and diastolic BP AUC between baseline and the end of treatment

    Time frame: 16 weeks

  3. change in night time ABPM systolic and diastolic BP AUC

    change in night time ABPM systolic and diastolic BP AUC between baseline and the end of treatment

    Time frame: 16 weeks

  4. change in HBPM SBP and DBP AUC

    change in HBPM SBP and DBP AUC over the entire study period

    Time frame: 16 weeks

  5. changes in serum electrolytes

    changes in serum electrolytes over the entire study period

    Time frame: 16 weeks

08

Study locations

1 site
  • Glasgow Clinical Research Facility
    Glasgow, G51 4TF, United Kingdom
09

References and documents

Publications

  • McCallum L, Brooksbank K, McConnachie A, Aman A, Lip S, Dawson J, MacIntyre IM, MacDonald TM, Webb DJ, Padmanabhan S. Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD). Am J Hypertens. 2021 Feb 18;34(1):92-99. doi: 10.1093/ajh/hpaa166. PubMed 33084880 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Oct 2021, 54 months.

Of 126 non-industry phase 4 interventional studies under Hypertension, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 54 months is above that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2017
First posted
Nov 28, 2017
StartActual
Apr 5, 2017
Primary completionActual
Oct 30, 2021
CompletionActual
Oct 30, 2021
Last update
Sep 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03354897
Collaborators
University of Glasgow, British Heart Foundation
Responsible party
Sponsor
First posted
Nov 28, 2017
Start date
Apr 5, 2017
Primary completion
Oct 30, 2021
Completion
Oct 30, 2021
Last update
Sep 25, 2023

Study contacts

Sandosh Padmanabhan, MbChB PhD
study chair · University of Glasgow

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Torsemide

Start the discussion